What's Happening?
Enhertu (trastuzumab deruxtecan), a HER2-directed antibody-drug conjugate (ADC) developed by Daiichi Sankyo and AstraZeneca, has been honored with the 2026 International Prix Galien Award for Best Biotechnology Product. This marks the second Prix Galien award
for Enhertu, following its receipt of the Prix Galien USA Award in 2024. The award, presented by The Galien Foundation, recognizes significant achievements in biomedical and medical technology that enhance human health. Enhertu was selected from six nominees by an international committee and the award ceremony took place at the American Museum of Natural History in New York on October 29, 2026. Since its initial U.S. approval in 2019, Enhertu has been instrumental in redefining the treatment and classification of metastatic breast cancer, particularly by establishing HER2 low and HER2 ultralow breast cancer as distinct clinical segments. The drug has also demonstrated practice-changing results in HER2-positive breast cancer, HER2-positive metastatic gastric cancer, and as the first HER2-directed tumor-agnostic medicine for HER2-positive solid tumors.
Why It's Important?
The recognition of Enhertu with the International Prix Galien Award underscores its significant impact on oncology and highlights the advancements in targeted cancer therapies. This award, often considered the biopharmaceutical industry's equivalent of the Nobel Prize, validates the innovative DXd ADC Technology developed by Daiichi Sankyo. For U.S. patients, Enhertu's approvals across various HER2-positive cancers, including breast, gastric, and non-small cell lung cancer (NSCLC), provide crucial treatment options where alternatives may be limited. The drug's ability to address HER2-low and HER2-ultralow breast cancer segments signifies a broader applicability and potential for improved patient outcomes. The continued success and recognition of such therapies can stimulate further research and development in the ADC field, potentially leading to more effective and targeted treatments for a wider range of cancers, benefiting both patients and the pharmaceutical industry in the U.S.
What's Next?
Enhertu's ongoing global clinical development program continues to evaluate its efficacy and safety as a monotherapy, in combination, or sequentially with other cancer medicines across various HER2-targetable cancers. Continued approval for certain indications in the U.S., such as HER2-mutant NSCLC and HER2-positive solid tumors, may be contingent upon verification and description of clinical benefit in confirmatory trials. The collaboration between Daiichi Sankyo and AstraZeneca, which includes the joint development and commercialization of Enhertu, is expected to continue driving its availability and further research. The sustained success of Enhertu could also influence future investment and regulatory pathways for other antibody-drug conjugates, potentially accelerating the introduction of new oncology treatments to the U.S. market.
Beyond the Headlines
The success of Enhertu reflects a broader shift in cancer treatment towards highly targeted therapies that leverage specific molecular characteristics of tumors. The concept of 'tumor-agnostic' approvals, where a drug is effective across different cancer types based on a shared biomarker like HER2, represents a paradigm shift in oncology drug development. This approach can streamline clinical trials and accelerate access to treatments for patients with rare or difficult-to-treat cancers. However, it also presents challenges in diagnostic testing and ensuring equitable access to advanced molecular profiling. The high cost of such innovative therapies also raises questions about healthcare affordability and reimbursement policies, which are critical considerations for U.S. healthcare stakeholders and patients.
